Filtered By:
Condition: Heart Failure
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 331 results found since Jan 2013.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Publication date: 2–8 February 2019Source: The Lancet, Volume 393, Issue 10170Author(s): Jane Armitage, Colin Baigent, Elizabeth Barnes, D John Betteridge, Lisa Blackwell, Michael Blazing, Louise Bowman, Eugene Braunwald, Robert Byington, Christopher Cannon, Michael Clearfield, Helen Colhoun, Rory Collins, Björn Dahlöf, Kelly Davies, Barry Davis, James de Lemos, John R Downs, Paul Durrington, Jonathan EmbersonSummaryBackgroundStatin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We u...
Source: The Lancet - February 2, 2019 Category: General Medicine Source Type: research

'Fake news and ageism' keeping statins from older people
Offering statins to all over-75s could prevent 8,000 deaths from heart failure and stroke, researchers sayThousands of deaths and the wrecking of many lives by disability could be averted if doctors routinely offered a daily statin pill to older people, scientists say.They blame misinformation about the side-effects of statins, together with society ’s ageism, for the low uptake among older people, who are at highest risk of heart attacks, heart failure and stroke.Continue reading...
Source: Guardian Unlimited Science - January 31, 2019 Category: Science Authors: Sarah Boseley Health editor Tags: Statins Heart attack Heart disease Stroke Older people Health Medical research Society Science UK news Source Type: news

Rationale and Design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study
Publication date: Available online 29 September 2018Source: American Heart JournalAuthor(s): Aruna D. Pradhan, Nina P. Paynter, Brendan M. Everett, Robert J. Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R. Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G. Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M RidkerAbstractObservational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective p...
Source: American Heart Journal - October 4, 2018 Category: Cardiology Source Type: research

Differences in management and outcomes for men and women with ST-elevation myocardial infarction.
CONCLUSION: Women with STEMI are less likely to receive invasive management, revascularisation, or preventive medication at discharge. The reasons for these persistent differences in care require investigation. PMID: 30025513 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - July 22, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

Scientific expert reaction to Cochrane Review on omega-3 fatty acids
This study provides no evidence to suggest that this dietary advice should change.”Read the press releaseSee the media coverageDeclared interestsProf Tim Chico: “No conflicts.”Dr Ian Johnson: “Ian Johnson has previously held honorary academic appointments in the medical school at the University of East Anglia.”Prof Tom Sanders: “Scientific governor of British Nutrition Foundation, Honorary Director of Nutrition HEART UK.”The Science Media CentreThe Science Media Centre is an independent venture working to promote the voices, stories and views from the scientific community to the news media when science is in ...
Source: Cochrane News and Events - July 17, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

The Association Between Inflammatory Markers and Hypertension. A Call for Anti-Inflammatory Strategies?
Authors: García NH, Juncos LI Abstract The most important goal of antihypertensive therapy is to prevent the complications associated with hypertension (stroke, myocardial infarction, end-stage renal disease, etc). For this, secondary targets such as left ventricular hypertrophy, proteinuria, dementia, and other signs of hypertension-induced organ damage help the physician to assess risks and monitor treatment efficacy. New treatment targets may be arising, however. One such target may be endothelial dysfunction. In effect, endothelial dysfunction not only may precede the elevation of blood pressure, but may also ...
Source: The Scientific World Journal - June 7, 2018 Category: Science Tags: ScientificWorldJournal Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

Small dense low ‐density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease
ConclusionssdLDL‐C was the most effective predictor of residual risk of future CE in stable coronary artery disease patients using statins and in high‐risk coronary artery disease patients with diabetes or hypertriglyceridemia. Geriatr Gerontol Int 2018; ••: ••–••.
Source: Geriatrics and Gerontology International - February 1, 2018 Category: Geriatrics Authors: Koshiro Sakai, Shinji Koba, Yuya Nakamura, Yuya Yokota, Fumiyoshi Tsunoda, Makoto Shoji, Yasuki Itoh, Yuji Hamazaki, Youichi Kobayashi Tags: Original Article: Epidemiology, Clinical Practice and Health Source Type: research

A New Form of This Miracle Nutrient Is 8 Times More Powerful …
CoQ10 has made the mainstream. You can find it everywhere. But the type of CoQ10 I want to tell you about has been completely ignored. That’s too bad, because this new form is 8 times better at getting into your blood and staying there. And that’s where it has its miracle-like anti-aging effects. This new form of CoQ10 may give you the opportunity to live disease-free for the rest of your life. Today, I’ll show you how this new “reduced” form of CoQ10 gives you greater power to prevent and reverse disease. You’ll also discover that it ramps up your energy levels and slows your aging process down by a remarkable...
Source: Al Sears, MD Natural Remedies - January 3, 2018 Category: Complementary Medicine Authors: Francisco Cabrera Tags: Nutrition antioxidants CoQ10 ubiquinol Source Type: news

Selective ß1-Blockers Are Not Associated With New-onset Diabetes Mellitus in Hypertensive Patients
Conclusions: In the era of newer ß-blockers, selective ß1-blockers were not associated with new-onset DM. More evidence is needed to verify this relationship and the underlying mechanisms.
Source: Journal of Cardiovascular Pharmacology - January 1, 2018 Category: Cardiology Tags: Original Article Source Type: research

Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
CONCLUSIONSAmong CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Inna Y. Gong, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, Winson Y. Cheung, Stuart Peacock, Marlous Hall, Chris P. Gale, Kelvin K. W. Chan Tags: Original Article Source Type: research

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation
Publication date: December 2017 Source:Canadian Journal of Cardiology, Volume 33, Issue 12 Author(s): Lena Rivard, Paul Khairy Atrial fibrillation (AF) and dementia are major health issues, with growing evidence suggesting a consistent association between AF and all forms of dementia. Although dementia and AF share several risk factors, the association appears to be independent of a history of clinical stroke and other comorbidities such as hypertension, heart failure, and diabetes. Proposed mechanisms linking AF to cognitive decline include altered hemodynamics resulting in cerebral hypoperfusion, inflammation, genetic f...
Source: Canadian Journal of Cardiology - December 3, 2017 Category: Cardiology Source Type: research

Adhering to the principles of clinical pharmacology - The Correct Fixed Combinations of Antihypertensive Drugs.
Abstract Introduction Hypertension is one of the primary modifiable risk factors for cardiac and renal diseases. The prevalence of hypertension appears to be around 30-45% of the general population, with a steep increase with ageing. The administration of blood pressure-lowering drugs is to reduce the risk of major clinical cardiovascular outcomes: stroke, myocardial infarction, heart failure and cardiovascular deaths. Hypertension guidelines recommend combination therapy in patients with high cardiovascular risk and with subclinical organ damage as well as when monotherapy fails. Areas covered As the etiology of ...
Source: Pharmacological Reviews - December 1, 2017 Category: Drugs & Pharmacology Authors: Paulina L, Elzbieta M, Anna TK, Banach M, Jolanta M Tags: Expert Rev Clin Pharmacol Source Type: research

Long-term risk and predictors of cardiovascular death in stable coronary artery disease: the CORONOR study
Conclusion: In stable CAD patients widely treated by secondary prevention medications, the main causes of CVD are death from HF and sudden death. The risk of CVD can be predicted by simple baseline variables. New therapeutic strategies are needed for the high-risk patients.
Source: Coronary Artery Disease - November 2, 2017 Category: Cardiology Tags: Original Research Source Type: research